Sign in

Private company

Arch Therapeutics, Inc.

Arch Therapeutics, Inc. is an American surgical and medical instruments and apparatus company.1 It is headquartered in Framingham, Massachusetts.1

Last updated Oct 21, 2026.

Overview

  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersFramingham, Massachusetts1
  • Incorporated inNV2
  • Business address235 Walnut Street, Suite 6, Framingham, Ma 017022
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

The following discussion should be read in conjunction with our consolidated financial statements and the related notes and other financial information included in this Annual Report.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-6661.7%Operating margin4
-9221.4%Net margin4
383.8%Revenue growth, 20234
-$3.4MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue1¢$78.2K
  • Research and development8¢$670.9K
  • Selling, general and admin53¢$4.4M
  • Interest38¢$3.1M

Out of $75.7K in revenue.4 The company lost money this year.

Financial statements

Revenue567894$75.7K in 2023
0$20.0K$40.0K$60.0K$80.0K2017: $0$020172018: $0$020182019: $0$020192020: $0$020202021: $11.6K$11.6K20212022: $15.7K$15.7K2022+35%2023: $75.7K$75.7K2023+384%
Operating income567894-$5.0M in 2023−31% since 2017
-$8.0M-$6.0M-$4.0M-$2.0M02017: -$7.3M-$7.3M20172018: -$7.4M-$7.4M2018+2%2019: -$6.4M-$6.4M2019−14%2020: -$5.4M-$5.4M2020−16%2021: -$6.4M-$6.4M2021+19%2022: -$5.7M-$5.7M2022−10%2023: -$5.0M-$5.0M2023−12%
Net income567894-$7.0M in 2023−10% since 2017
-$8.0M-$6.0M-$4.0M-$2.0M02017: -$7.8M-$7.8M20172018: -$4.8M-$4.8M2018−38%2019: -$4.5M-$4.5M2019−6%2020: -$4.7M-$4.7M2020+3%2021: -$6.2M-$6.2M2021+33%2022: -$5.3M-$5.3M2022−15%2023: -$7.0M-$7.0M2023+32%
Fiscal year2017201820192020202120222023
Revenue$05$06$07$08$11.6K9$15.7K4$75.7K4
Cost of revenue$26.3K9$51.5K4$78.2K4
Research and development$2.1M5$2.9M6$2.4M7$1.6M8$1.4M9$1.2M4$670.9K4
Selling, general and admin$3.7M8$5.0M9$4.5M4$4.4M4
Operating expenses$5.7M4$5.1M4
Operating income-$7.3M5-$7.4M6-$6.4M7-$5.4M8-$6.4M9-$5.7M4-$5.0M4
Interest$52.4K5$05$18.5K8$150.5K9$567.0K4$3.1M4
Net income-$7.8M5-$4.8M6-$4.5M7-$4.7M8-$6.2M9-$5.3M4-$7.0M4
Earnings per share-$0.028-$0.039-$4.404-$2.274
Earnings per share (diluted)-$0.028-$0.038

Compare Arch Therapeutics, Inc. with another company

Corporate structure

Arch Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Arch Therapeutics, Inc.

  • Bigger Capital, LLC Filed SC 13G/A on Arch Therapeutics, Inc., latest Nov 13, 2024
  • Michael Andrew Parker Filed SC 13G/A on Arch Therapeutics, Inc., latest Jan 22, 2024 (4 filings since Jan 12, 2022)
  • Andrew Stahl Filed SC 13G on Arch Therapeutics, Inc., latest Aug 9, 2023
  • Brandt Wilson Filed SC 13G on Arch Therapeutics, Inc., latest Jul 25, 2023
  • BIGGER CAPITAL FUND L P Filed SC 13G on Arch Therapeutics, Inc., latest Jul 14, 2023
  • Oasis Capital, LLC Filed SC 13G on Arch Therapeutics, Inc., latest Jul 12, 2023
  • Arch Therapeutics, Inc. Framingham, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Arch Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$33.8K9 Sep 30, 2022$33.8K9 Sep 30, 20210%
Accumulated depreciation$31.7K9 Sep 30, 2022$28.5K9 Sep 30, 2021+11.2%
Property and equipment, net$4.6K4 Sep 30, 2023$2.0K4 Sep 30, 2022+125.0%
Operating-lease assets (leased space)$09 Sep 30, 2022$09 Sep 30, 2021

Inventory

ItemLatestA year beforeChange
Inventory, total$1.4M4 Sep 30, 2023$1.4M4 Sep 30, 2022−3.6%
Work in process$1.3M4 Sep 30, 2023$1.4M4 Sep 30, 2022−5.9%
Finished goods$41.0K4 Sep 30, 2023$9.1K4 Sep 30, 2022+352.0%

Leadership

Who has led Arch Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Terrence W. Norchi2013–2023

President

  1. Terrence W. Norchi2015–2023

Chief financial officer

  1. Alan Barber2013
  2. Richard E. Davis2014–2019
  3. Michael S. Abrams2021–2023

Chief operating officer

  1. William M. Cotter2013–2014
201520202025
Board members and other officers (9)

Former names

  • ALMAH,INCJan 5, 2012 to May 24, 20132

Timeline

  1. May 23, 20258-K Bankruptcy or receivership; Debt or obligation accelerated; Listing notice or transfer28
  2. Feb 7, 20258-K Executive or director change29
  3. Jan 23, 20258-K Entered a material agreement; New debt or obligation; Unregistered sale of shares30
  4. Nov 7, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares31
  5. Nov 4, 20248-K Entered a material agreement32
  6. Sep 26, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares33
  7. Sep 19, 20248-K Entered a material agreement34
  8. Sep 13, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares35
  9. Aug 30, 20248-K Executive or director change36
  10. Aug 20, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares37
  11. Aug 16, 20248-K Executive or director change38
  12. Aug 16, 20248-K Entered a material agreement39
  13. Jun 26, 2013New chief executive Terrence W. Norchi becomes CEO14

Filings

154 filings to the SEC since October 2021: 5 annual reports, 9 quarterly reports, 60 major events, 22 insider forms, 9 large holders, 1 private raises, 48 other. The latest 20:

  1. Jan 12, 202615-12G EDGAR
  2. May 23, 20258-K EDGAR
  3. May 23, 2025RW EDGAR
  4. Feb 7, 20258-K EDGAR
  5. Jan 23, 20258-K EDGAR
  6. Dec 31, 2024NT 10-K EDGAR
  7. Nov 13, 2024SC 13G/A EDGAR
  8. Nov 7, 20248-K EDGAR
  9. Nov 4, 20248-K EDGAR
  10. Sep 26, 20248-K EDGAR
  11. Sep 19, 20248-K EDGAR
  12. Sep 13, 20248-K EDGAR
  13. Aug 30, 20248-K EDGAR
  14. Aug 20, 20248-K EDGAR
  15. Aug 19, 202410-Q EDGAR
  16. Aug 16, 20248-K EDGAR
  17. Aug 16, 20248-K EDGAR
  18. Aug 14, 2024NT 10-Q EDGAR
  19. Aug 2, 20248-K EDGAR
  20. Jul 22, 20248-K EDGAR

The 154 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 3 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 31, 2023ABRAMS MICHAEL SCHIEF FINANCIAL OFFICERBuy10,292$0.28$2.9KForm 4
Aug 31, 2023Norchi Terrence WPRESIDENT AND CHIEF EXECUTIVEBuy6,862$0.28$1.9KForm 4
Aug 31, 2023Hicks LaurenceDirectorBuy10,292$0.28$2.9KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 6, 2022Raised $4.2 million in a private offering of equity Form D: 16 investors so far Form D

SEC filer profile

How Arch Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARArch Therapeutics, Inc.1
  • CIK0001537561
  • Employer ID (EIN)46-05241021
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inNevada1
  • Fiscal year endsSeptember 301
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address235 Walnut Street, Suite 6, Framingham, MA 017021
  • Phone617-431-23131
  • Shares outstanding4,444,364 as of Aug 19, 202411
  • Public float$4.0M as of Mar 31, 202346
  • On EDGAR sinceJan 5, 20121
  • Filings558 in all: 8-K (156), 424B3 (147), 4 (58), 10-Q (38), EFFECT (16), CORRESP (13), 10-K (12), 3 (12)1
    All 35 form types

    S-1/A (12), SC 13G/A (12), S-8 (9), UPLOAD (9), S-1 (8), D (7), POS AM (6), SC 13G (5), 424B5 (4), NT 10-Q (4), S-3 (4), S-3/A (4), 10-K/A (3), 8-K/A (2), DEF 14A (2), NT 10-K (2), PRE 14A (2), SC 13D (2), 15-12G (1), 4/A (1), 424B4 (1), 8-A12G (1), CT ORDER (1), DEF 14C (1), DEFR14A (1), PRE 14C (1), RW (1)

  • Latest filingsAnnual report (10-K) Feb 15, 2024
    Quarterly report (10-Q) Aug 19, 2024
    Proxy statement (DEF 14A) Aug 30, 2022
    Latest 8-K (8-K) May 23, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46